Ebastine/Phenylephrine Dosage

What is the dose of your medication?
sponsored

Consists of Ebastine, Phenylephrine

Dosage of Ebastine in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Histamine-induced wheal & flare 10 mg/day. Pruritus 10 mg/day. Severe pruritus Initially, 20 mg/day. Reduce to 10 mg/day upon improvement of itching. Allergic rhinitis or chronic idiopathic urticaria 10 mg as a single daily dose. Seasonal allergic rhinitis 20 mg/day.

Ebastine interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Ebastine, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.

Concomitant use of ketoconazole, itraconazole, clarithromycin or erythromycin may increase plasma levels of ebastine and cause QTc interval prolongation.

Dosage of Phenylephrine in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.

Usual Adult Dose for Hypotension:

IM or subcutaneous: 2 to 5 mg every 1 to 2 hours as needed.

IV bolus: 0.2 mg/dose (range: 0.1 to 0.5 mg/dose) every 10 to 15 minutes as needed (initial dose should not exceed 0.5 mg)

IV infusion: 100 to 180 mcg/min initially. The usual maintenance dose is 40 to 60 mcg/min.

Alternatively, 0.5 mcg/kg/minute; titrate to desired response. Dosing ranges between 0.4 to 9.1 mcg/kg/minute have been reported.

Usual Adult Dose for Shock:

IM or subcutaneous: 2 to 5 mg every 1 to 2 hours as needed.

IV bolus: 0.2 mg/dose (range: 0.1 to 0.5 mg/dose) every 10 to 15 minutes as needed (initial dose should not exceed 0.5 mg)

IV infusion: 100 to 180 mcg/min initially. The usual maintenance dose is 40 to 60 mcg/min.

Alternatively, 0.5 mcg/kg/minute; titrate to desired response. Dosing ranges between 0.4 to 9.1 mcg/kg/minute have been reported.

Usual Adult Dose for Supraventricular Tachycardia:

0.25 to 0.5 mg IV over 30 seconds.

Usual Adult Dose for Nasal Congestion:

Tablets or oral liquid: 10 to 20 mg orally every 4 hours as needed.

Phenylephrine 7.5 mg/5 mL oral liquid:

15 mg orally every 6 hours not to exceed 60 mg daily.

Phenylephrine 10 mg oral tablet:

10 mg orally every 4 to 6 hours not to exceed 4 doses daily.

Phenylephrine 10 mg oral disintegrating strip:

10 mg orally every 4 hours not to exceed 6 doses daily.

Phenylephrine 10 mg/5 mL oral suspension, extended release:

10 to 20 mg orally every 12 hours.

Phenylephrine tannate 10 mg oral tablet, chewable, extended release:

10 to 20 mg orally every 12 hours.

Phenylephrine tannate 7.5 mg/5 mL oral suspension, extended release

7.5 to 15 mg orally every 12 hours.

Usual Pediatric Dose for Hypotension:

IM or subcutaneous: 0.1 mg/kg every 1 to 2 hours as needed. Maximum dose: 5 mg.

IV bolus: 5 to 20 mcg/kg/dose every 10 to 15 minutes as needed.

IV: 0.1 to 0.5 mcg/kg/min titrated to effect.

Usual Pediatric Dose for Shock:

IM or subcutaneous: 0.1 mg/kg every 1 to 2 hours as needed. Maximum dose: 5 mg.

IV bolus: 5 to 20 mcg/kg/dose every 10 to 15 minutes as needed.

IV: 0.1 to 0.5 mcg/kg/min titrated to effect.

Usual Pediatric Dose for Supraventricular Tachycardia:

5 to 10 mcg/kg IV over 30 seconds.

Usual Pediatric Dose for Nasal Congestion:

phenylephrine 1.25 mg/0.8 mL oral liquid:

2 years to 5 years: 1.6 mL orally every 4 hours not to exceed 6 doses daily.

Chewable tablets or oral liquid:

6 years to 11 years: 10 mg orally every 4 hours as needed.

12 years or older: 10 to 20 mg orally every 4 hours as needed.

Phenylephrine 7.5 mg/5 mL oral liquid:

2 years to 5 years: 3.75 mg orally every 6 hours not to exceed 15 mg daily.

6 years to 11 years: 7.5 mg orally every 6 hours not to exceed 30 mg daily.

12 years or older: 15 mg orally every 6 hours not to exceed 60 mg daily.

Phenylephrine 10 mg oral tablet:

12 years or older: 10 mg orally every 4 to 6 hours not to exceed 4 doses daily.

Phenylephrine 10 mg oral tablet, disintegrating:

2 years to 5 years: 5 mg orally every 4 hours as needed.

6 years to 11 years: 10 mg orally every 4 hours as needed.

12 years or older: 10 to 20 mg orally every 4 hours as needed.

Phenylephrine 10 mg/5 mL oral suspension, extended release:

12 years or older: 10 to 20 mg orally every 12 hours.

6 years to 11 years: 5 to 10 mg orally every 12 hours.

Phenylephrine 10 mg oral disintegrating strip:

12 years or older: 10 mg orally every 4 hours not to exceed 6 doses daily.

Phenylephrine tannate 10 mg oral tablet, chewable, extended release:

6 years to 11 years: 5 to 10 mg orally every 12 hours.

12 years or older: 10 to 20 mg orally every 12 hours.

Phenylephrine tannate 7.5 mg/5 mL oral suspension, extended release

2 years to 5 years: 1.25 to 2.5 mL orally every 12 hours.

6 years to 11 years: 2.5 to 5 mL orally every 12 hours.

12 years or older: 5 to 10 mL orally every 12 hours.

phenylephrine 1.25 mg oral disintegrating strip:

2 years to 3 years: 2.5 mg orally every 4 hours, not to exceed 15 mg in 24 hours.

phenylephrine 2.5 mg oral disintegrating strip:

2 years to 5 years: 2.5 mg orally every 4 hours, not to exceed 15 mg in 24 hours.

6 years to 11 years: 5 mg orally every 4 hours, not to exceed 30 mg in 24 hours.

phenylephrine 1.25 mg oral tablet, chewable:

12 years or older: 5 mg orally every 4 hours not to exceed 6 doses daily.

phenylephrine 2.5 mg/5 mL oral liquid:

4 years to 5 years: 5 mL orally every 4 hours, not to exceed 6 doses in 24 hours.

6 years to 11 years: 10 mL orally every 4 hours, not to exceed 6 doses in 24 hours.

What other drugs will affect Phenylephrine?

Ask a doctor or pharmacist if it is safe for you to use phenylephrine rectal if you are also using any of the following drugs:

This list is not complete and other drugs may interact with phenylephrine rectal. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Phenylephrine interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Phenylephrine, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic). Monitor therapy

Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy

AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy

Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Consider therapy modification

Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy

Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Systemic). Monitor therapy

CloZAPine: May diminish the therapeutic effect of Phenylephrine (Systemic). Monitor therapy

Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification

Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy

Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination

FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy

Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy

Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated. Avoid combination

Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Avoid combination

Ioflupane I 123: Phenylephrine (Systemic) may diminish the diagnostic effect of Ioflupane I 123. Monitor therapy

Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification

Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid. Avoid combination

Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification

Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Monitor therapy

Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy

Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy

Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy

Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. Monitor therapy


sponsored

References

  1. FDA/SPL Indexing Data. "TQD7Q784P1: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
  2. MeSH. "Histamine H1 Antagonists". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Ebastine/Phenylephrine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ebastine/Phenylephrine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 2 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved